glp 1 ra que es Xia & He Publishing GLP-1 Vs Tirzepatide: Powerful Guide

Description

J., Kemmeries, G., Holst, J

Int J Eat Disord

In the international survey, 19.9% of participants used tirzepatide

The evidence for GLP-1 medications in treating NASH (the more severe form of fatty liver disease) is particularly impressive: Liraglutide achieved histological resolution of steatohepatitis in 39% of cases after 48 weeks, compared to just 9% in placebo groups 20 Patients taking liraglutide had 4.5 times higher likelihood of NASH resolution than those on placebo 20 Semaglutide demonstrated NASH resolution in 59% of participants versus 17% in placebo groups 21 We offer FibroScan technology to measure liver stiffness and fat content, helping us monitor your progress while on GLP-1 therapy